|
Evaluation of blood stream infections. |
|||
| Item |
Group 1 (heparin) |
Group 2 (TauroLock™) |
P value |
|
|
|||
| No. of BSI events |
30 |
25 |
|
| No. (%) of patients with at least 1 BSI |
24 (27) |
21 (24) |
0.74 |
| No. (%) of BSI with CoNS* or MRSE§ |
14 (47) |
3 (11) |
0.004 |
| CoNS: 4 (13) |
CoNS: 3 (11) |
||
| MRSE: 10 (33) |
MRSE: 0 (0) |
||
| Incidence density‡ for All BSI events (CI95) |
4.93 (3.33–7.04) |
3.82 (2.52–5.56) |
0.35 |
| Incidence density‡ calculated with the number of specific isolates |
|||
| BSI with CoNS/MRSE |
2.30 (1.26–3.86) |
0.45 (0.09–1.31) |
0.004 |
| BSI other Gram positive |
0.66 (0.18–1.68) |
1.19 (0.52–2.35) |
0.32 |
| BSI E. coli |
0.66 (0.18–1.68) |
1.49 (0.72–2.74) |
0.15 |
| BSI all Gram negative |
1,97 (1.02–3.44) |
2.24 (1.25–3.69) |
0.74 |
|
Group 1 = heparin (2004–2005) vs. group 2 = TauroLock™ (2005–2006) * CoNS = coagulase-negative Staphylococci (methicillin-sensitive) §MRSE = methicillin-resistant coagulase-negative Staphylococci + The percentage refers to all documented BSI in this group (100%). ‡ The ID refers to the number of events per 1000 inpatient CVAD utilization days. Δ IQR = interquartile range, 25–75. Percentile | |||
Simon et al. BMC Infectious Diseases 2008 8:102 doi:10.1186/1471-2334-8-102 |
|||